Chloropyramine Chloropyramine Chloropyramine is a classical ("old", or first-generation) antihistamine drug approved in some Eastern European countries (like Russia) for the treatment of allergic conjunctivitis, allergic rhinitis, bronchial asthma, and other atopic (allergic) conditions. Related indications for clinical use include angioedema (Quincke's edema), allergic reactions to insect bites, food and drug allergies, and anaphylactic shock. Chloropyramine is known as a competitive reversible H receptor antagonist (also known as an H inverse agonist), meaning that it exerts its pharmacological action by competing with histamine for the H subtype histamine receptor. By blocking the effects of histamine, the drug inhibits the vasodilation, increased
Allergic bronchopulmonary aspergillosis placing global burden at around 4.8 million people affected. The Eastern Mediterranean region had the lowest estimated prevalence, with a predicted case burden of 351,000; collectively, the Americas had the highest predicted burden at 1,461,000 cases. These are likely underestimates of total prevalence, given the exclusion of CF patients and children from the study, as well as diagnostic testing being limited in less developed regions. Allergic bronchopulmonary aspergillosis Allergic bronchopulmonary aspergillosis (ABPA) is a condition characterised by an exaggerated response of the immune system (a hypersensitivity response) to the fungus "Aspergillus" (most commonly "Aspergillus fumigatus"). It occurs most often in